StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
2927.T$840.00-0.83%
Fair $840.00+0.0%

2927.T

AFC-HD AMS Life Science Co., Ltd.

Consumer Defensive / Packaged FoodsTokyo

$840.00

-7.00 (-0.83%)

Fairly Valued+0.0%Fair Value $840.00Fund rank 20/100 · Data gapFallback financials|
SA 37/D
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 14%

FCF escenarios

weak_data · normalized FCF $-1.8B · quality 29.0/100

Data gap 20/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 9/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

37/100

D

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 2927.TLocal privado en este navegador · AFC-HD AMS Life Science Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$12.2B

P/E

8.8x

↓

EV/EBITDA

6.4x

↓

ROE

9.6%

↑

Gross Margin

34.5%

↑

Debt/Equity

1.59

↑
52-Week Range$840
$810$918

TradingView lightweight chart

2927.T price, volumen y niveles de valoración

Último $840.00Periodo -45.2%
Fair value: $840.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+12.4%

FCF CAGR

—

FCF margin

-5.4%

FCF / Net income

-1.21x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $32.66B · net income $1.45B · FCF $-1.75B

2022-FY → 2025-FY

Gross margin

34.5%-2.8% pts

Operating margin

7.4%+3.0% pts

Net margin

4.4%+1.2% pts

FCF margin

-5.4%-7.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$32.66B$32.66B$30.19B$25.58B$23.02B
Net Income$1.45B$1.45B$1.25B$1.10B$735.4M
EBITDA$3.80B$3.80B$3.10B$2.59B$2.30B
EPS102.97102.9789.2078.4652.08
Gross Margin34.5%34.5%34.8%36.4%37.3%
Operating Margin7.4%7.4%6.3%6.4%4.4%
Net Margin4.4%4.4%4.1%4.3%3.2%
Balance Sheet
Debt/Equity1.591.591.641.491.38
Current Ratio0.850.85———
Cash Flow
Free Cash Flow$-1.75B$-1.75B$-1.87B$-1.07B$534.4M
Returns
ROE9.6%9.6%9.0%8.4%5.9%
Valuation
P/E8.828.829.0510.0614.34
EV/EBITDA6.436.437.127.517.52
P/B0.780.780.810.850.85
Growth & Yield
Revenue Growth8.2%8.2%18.0%11.1%—
EPS Growth15.4%15.4%13.7%50.7%—
Dividend Yield4.3%4.3%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-10.2%

fácil

EPS terminal req.

$74.54

Spread vs growth

25.6%

5Y implied EPS CAGR

-2.6%

fácil

EPS terminal req.

$90.19

Spread vs growth

18.1%

10Y implied EPS CAGR

3.5%

fácil

EPS terminal req.

$145.25

Spread vs growth

11.9%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +3.0%

Total return

+3.0%

Start / end P/E

9.5x → 8.2x

EPS bridge

89.20 → 102.97

Residual

-2.2%

EPS growth+15.4%
Multiple rerating-14.5%
Dividend+4.3%
Residual / FX / buybacks / cross-term-2.2%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.